Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Ibrutinib, and Rituximab in Relapsed/Refractory DLBCL
NCT03136497Phase 1Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Sep 2017
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in diffuse large B-cell lymphoma (DLBCL), sponsored by Hackensack Meridian Health. Started Sep 2017; status: terminated.
02
Drugs
venetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03136497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136497.